SAB Biotherapeutics Inc. held a special meeting of stockholders on September 26, 2025. At the meeting, stockholders approved an amendment to the company's 2021 Omnibus Equity Incentive Plan, increasing the maximum number of shares available to plan participants and raising the limit for shares issuable under the annual evergreen increase. Stockholders also approved the potential issuance of common stock upon conversion of Series B Convertible Preferred Stock at less than the minimum price under Nasdaq rules, which may be deemed a change of control. Both proposals received stockholder approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-220721), on September 26, 2025, and is solely responsible for the information contained therein.